



INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES (Int. J. of Pharm. Life Sci.)

Formulation Development and Evaluation of MDF of Cariprazine

Manoj Sharma^{1*} and Gajanand Engla²

1, SOS in Pharmaceutical Sciences, Jiwaji University, Gwalior (M.P.) - India

2, School of Pharmacy Devi Ahilya VishwaVidyalaya, Indore, (M.P.) - India

Abstract

Mouth dissolving film is now a days preferred route of drug administration due to patient compliance. The developed film formulation is a patient-friendly formulation that would be useful for people who have difficulty of swallowing. The results have shown that the HPMC-K4M is good film former and shows bioadhesion property. In combination with PEG-400, it has shown promising fast drug release within 10 min. and good folding endurance. Hence a semi-synthetic cellulose derivative which is affordable and abundantly available can be used as a potential drug release modifier and also used to improve flexibility and processability in the mouth dissolving films. Successful formulation of Cariprazine mouth dissolving films may prevent first pass metabolism to a large possible extent. From the present study it can be concluded that HPMC-K4M based mouth dissolving films of Cariprazine can be successfully prepared with considerable good stability and improved bioavailability

Keywords: Mpouth dissolving, Cariprazine, Evaluation

Introduction

Fast-dissolving drug-delivery systems were first developed in the late 1970s as an alternative to tablets, capsules, and syrups for pediatric and geriatric patients who experienced difficulties in swallowing traditional oral solid-dosage forms. The novel technology of oral fast-dispersing dosage forms is also known as fast dissolve, rapid dissolve, rapid melt or quick disintegration. However, the function and concept of all these dosage forms are similar. By definition, a solid dosage form that dissolves or disintegrates quickly in the oral cavity, resulting in solution or suspension without the need for the administration of water, is known as an oral fast-dispersing or fast-dissolving dosage form.¹⁻³

Cariprazine is an atypical antipsychotic used in the treatment of schizophrenia and manic or mixed episodes of bipolar disorder. Cariprazine has been associated with a low rate of serum aminotransferase elevations during therapy, but it has not been linked to instances of clinically apparent acute liver injury.

Psychosis is a condition characterized by the hallucination, dementia etc. seizures. It requires quick management of in order to avoid the risk of permanent brain damage. Pharmacotherapy with anti-psychotic drugs remains the major treatment modality for psychosis. Management of Psychosis differs from the treatment of other diseased conditions. Newer Anti-psychotic is an ideal drug candidate for an orally dissolving film formulation. The formulation of anti-psychotic as an orally dissolving strip, required to be placed on the patient's tongue without swallowing for dose administration, would significantly facilitate dose administration, with subsequent improvement in patient compliance. Thus, the aim of this work was to design, develop and characterize mouth dissolving film of Anti-psychotic drugs i.e., Cariprazine

Material and Methods

Identification of Drug (Physical Appearance)

Through visual inspection, the physical appearance of pure drug will be carried out as per Indian Pharmacopoeia.

Determination of melting point

Melting point of drugs will be determined using digital melting point apparatus by capillary fusion method.

Determination of solubility

* Corresponding Author

E.mail: manojdrde@gmail.com

7126

The dissolution and diffusion fluid for drug release and permeation studies respectively were selected based on solubility data of Cariprazine in various fluids. The solubility of drug sample was determined by adding 100 mg of drug sample in successively increasing amount in various fluids. The volume of solvent required to dissolve the drug was recorded and solubility was determined.

Determination of partition coefficient

The partition coefficient of drug was determined in n-Octanol as a non-aqueous phase and phosphate buffer solution pH 7.4 (PBS pH 7.4) as an aqueous phase. These two phases were mixed in equal quantities and kept for saturation with each other in separating funnel. After mixing the system remain undisturbed for 30 minutes. The partition coefficient was determined by taking 10 mg of drug in separating funnels containing 10 ml portion of each of n-Octanol and PBS pH 7.4. The separating funnels were shaken on mechanical shaker for 24 h. Two phases were separated and aqueous phase was filter through Whatman filter paper and the amount of the drug in aqueous phase was determined, after appropriate dilution

by spectrophotometrically at λ_{max} 318 and 248 nm by using phosphate buffer solution pH 7.4 as a blank.

Determination of UV absorption maxima

The accurately weighed quantity 100 mg of drug sample was dissolved in mixture of water and acetonitrile (1:1) (3 in 200,000) and volume make upto 100 ml using water and acetonitrile in 100 ml volumetric flask to obtain a stock solution 100 $\mu\text{g/ml}$. Then 1 ml of this stock solution was pipetted out in a 10 ml volumetric flask and volume was made upto the mark to obtained the concentration 10 $\mu\text{g/ml}$. The resulting solution was then scanned between 200-400 nm using UV-visible spectrophotometer (Model-1700, Shimadzu, Japan). The UV spectrum sample was recorded and obtained λ_{max} was matched with the UV spectrum as reported in official monograph.

Formulation of mouth dissolving films

The mouth dissolving films of will be prepared by semi solid solvent casting technique. Different viscosity grades of polymers as film formers and plasticizers employed in the film.

Table 1: Formulation of mouth dissolving film of Cariprazine fumarate

| Ingredients | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 |
|---------------------|------|------|------|------|------|------|------|------|------|
| Drug (mg) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| HPMC E5 (gm) | 0.5 | 0.75 | 1 | - | - | - | 1 | 0.5 | 0.75 |
| HPMC K4M (gm) | - | - | - | 0.5 | 0.75 | 1 | - | - | - |
| PEG 400 (ml) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Citric acid (mg) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Aspartame (mg) | 10 | 20 | 30 | 10 | 20 | 30 | 10 | 20 | 30 |
| Mannitol (mg) | 100 | 75 | 50 | 100 | 75 | 50 | 100 | 75 | 50 |
| Orange Flavor (ml) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Methyl Paraben (mg) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| Propyl Paraben (mg) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| DW (ml) | qs | qs | qs | qs | qs | qs | qs | qs | qs |

7126**Evaluation of mouth dissolving films**

The formulations were evaluated for thickness, weight variation, drug content, measurement of mechanical properties, folding endurance, physical appearance and texture analysis of the films, *in vitro* disintegration test and *in vitro* dissolution studies as per standard procedure as described earlier.

Results and Discussion

Through visual inspection, the physical appearance of pure drug was carried out as per Indian Pharmacopoeia. In this study color odor and taste was evaluated by our sense i.e., eye, tongue and nose. It was revealed that the drug is white in color having characteristics odor and bitter taste. The various results of evaluation parameters were presented in table 2 and 3

Table 2: Evaluation parameters of MDF of Cariprazine

| Formulation Code | Thickness (mm) | Weight variations (mg) | Drug content (%) | Tensile strength (N/mm ²) | Folding endurance | Surface texture | Surface pH | DT (Sec.) |
|------------------|----------------|------------------------|------------------|---------------------------------------|-------------------|-----------------|------------|-----------|
| F1 | 0.15±0.01 | 30.7±0.39 | 95.20±0.78 | 8.75±0.01 | 181±1.72 | Smooth | 7.0±0.29 | 12±0.91 |
| F2 | 0.16±0.04 | 31.8±0.29 | 94.38±0.59 | 8.50±0.01 | 183±1.92 | Smooth | 7.1±0.39 | 18±0.93 |
| F3 | 0.18±0.20 | 37.2±0.17 | 96.38±0.29 | 9.10±0.02 | 179±1.01 | Smooth | 6.2±0.39 | 19±1.02 |
| F4 | 0.17±0.22 | 41.8±0.38 | 97.62±0.89 | 9.11±0.003 | 183±1.1.82 | Smooth | 7.2±0.22 | 17±1.28 |
| F5 | 0.16±0.10 | 52.3±0.48 | 95.16±0.20 | 9.15±0.03 | 193±1.02 | Smooth | 6.7±0.39 | 14±0.89 |
| F6 | 0.19±0.03 | 53.6±0.29 | 99.18±0.28 | 9.21±0.01 | 220±1.78 | Smooth | 7.0±0.29 | 10±0.92 |
| F7 | 0.18±0.19 | 31.2±0.18 | 97.29±0.11 | 8.96±0.03 | 197±1.20 | Smooth | 6.3±0.18 | 16±1.10 |
| F8 | 0.17±0.18 | 33.8±0.11 | 98.33±0.19 | 8.98±0.82 | 201±1.83 | Smooth | 6.4±0.49 | 18±1.29 |
| F9 | 0.18±0.01 | 39.5±0.67 | 96.10±0.39 | 9.10±0.04 | 199±1.20 | Smooth | 6.9±0.51 | 16±1.29 |

Note: All values are Mean ±SEM, n=3

In-vitro drug release study showed that as the concentration of polymer increases, drug release from mouth dissolving films increases. An

immediate drug release was successfully observed for all HPMC films. The results were mentioned in the table 3

Table 3: Invitro drug release

| Time (Mts) | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 |
|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 26.35 | 31.67 | 49.37 | 30.10 | 38.74 | 51.29 | 27.54 | 33.43 | 47.34 |
| 4 | 36.52 | 42.18 | 58.30 | 41.09 | 4.407 | 66.10 | 42.85 | 44.29 | 59.89 |
| 6 | 52.89 | 58.93 | 76.28 | 57.03 | 66.29 | 74.49 | 55.92 | 59.54 | 77.20 |
| 8 | 66.01 | 78.49 | 89.84 | 69.19 | 84.39 | 89.20 | 69.94 | 81.10 | 91.38 |
| 10 | 74.13 | 89.10 | 94.89 | 82.29 | 93.49 | 97.44 | 78.10 | 91.20 | 93.20 |

Conclusion

From the present study it can be concluded that HPMC-K4M based mouth dissolving films of Cariprazine can be successfully prepared with considerable good stability and improved bioavailability

Reference

1. A. Arya, A. Chandra, V. Sharma, and K. Pathak, "Fast dissolving oral films: an innovative drug delivery system and dosage form," International Journal of ChemTech Research, vol. 2, no. 1, pp. 576–583, 2010.
2. K. Sharma, W. R. Pfizer, and T. K. Ghosh, "Quick-dispersing oral drug delivery systems," in Drug Delivery to the Oral Cavity Molecule to Market, vol. 145, pp. 262–287, 2005.
3. F. Cilurzo, I. E. Cupone, P. Minghetti, F. Selmin, and L. Montanari, "Fast dissolving films made of maltodextrins," European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 3, pp. 895–900, 2008.
4. S. K. Yellanki, S. Jagtap, and R. Masareddy, "Dissolm: a novel approach for delivery of

- phenobarbital; design and characterization,” Journal of Young Pharmacists, vol. 3, no. 3, pp. 181–188, 2011.
5. T. Hanawa, “Development of a new and kindly oral dosage form for elderly,” Journal of Pharmaceutical Science and Technology, vol. 13, no. 4, pp. 251–258, 1997.
6. H. Goel, P. Rai, V. Rana, and A. K. Tiwary, “Orally disintegrating systems: innovations in formulation and technology,” Recent Patents on Drug Delivery and Formulation, vol. 2, no. 3, pp. 258–274, 2008.
7. R. Mishra and A. Amin, “Formulation development of taste-masked rapidly dissolving films of cetirizine hydrochloride,” Pharmaceutical Technology, vol. 33, no. 2, pp. 48–56, 2009.

How to cite this article

Sharma M. and Engla G. (2014). Formulation Development and Evaluation of MDF of Cariprazine. *Int. J. Pharm. Life Sci.*, 5(12):4100-4103.

Source of Support: Nil; Conflict of Interest: None declared

Received: 07.10.14; Revised: 29.11.14; Accepted: 11.12.14